Menu

First Blood Test for Concussion Approved by FDA

The diagnostic measures two proteins indicative of brain injury.

Feb 16, 2018
Kerry Grens

WIKIMEDIA, U.S. NAVY PHOTO BY PHOTOGRAPHER'S MATE 3RD CLASS JEREMY L. GRISHAMThis week (February 14), the US Food and Drug Administration (FDA) approved the first blood-based screening test for concussions. The diagnostic, which measures the abundance of the proteins UCH-L1 and GFAP, can help identify which patients should be sent for a CT scan to confirm any brain damage.

“This is going to change the testing paradigm for suspected cases of concussion,” Tara Rabin, a spokesperson for the FDA, tells The New York Times.

In the approval announcement, the FDA stated that the test accurately predicted the presence of “intracranial lesions” 97 percent of the time, and appropriately indicated that there were none 99 percent of the time. In doing so, the screen could avoid CT scans for one-third of people who have a possible mild traumatic brain injury.

“It doesn’t replace CT in all cases,” Jay Alberts, director of the Cleveland Clinic Concussion Center, tells NBC News. “The reason you do those scans is to rule out a clinically important brain injury, which would need surgery. . . . But in 99 percent of concussions you do not need a CT scan because they’re not clinically important, meaning there’s not an immediate need for surgery.”

The FDA says the test could be used for the general population, and will be especially helpful to the military.

See “Experimental Drug Relieves Blast-Related PTSD in a Rat Model of Traumatic Brain Injury

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
INTEGRA has responded to customers’ requests and developed two new 24-channel pipetting heads, extending the capabilities of its popular VIAFLO 96/384.
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.